Incyte Corp. has synthesized new GTPase KRAS inhibitors potentially useful for the treatment of cancer, inflammatory and immunological disorders.

Changchun Genescience Pharmaceuticals Co. Ltd. has discovered new ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibitors potentially useful for the treatment of mitochondrial and Parkinson’s disease.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has reported new proteolysis targeting chimera (PROTACs) compounds comprising a cereblon E3 ubiquitin ligase-binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety potentially useful for the treatment of cancer.

Chomix Biotech (Nanjing) Co. Ltd. has patented new irreversible fibroblast activation protein-α (FAPα) inhibitors potentially useful for the diagnosis or treatment of rheumatoid arthritis, atherosclerosis, cancer, myocardial infarction, kidney fibrosis, pulmonary and hepatic fibrosis, and among others.

Synnovation Therapeutics Inc. has identified new heterocyclic poly(ADP-ribose) glycohydrolase (PARG) inhibitors described as useful for the treatment of cancer.

Bristol Myers Squibb Co. (BMS) has disclosed new 1H-benzo[d]imidazole derivatives acting as calcium/calmodulin-dependent protein kinase type II (CAMK2) inhibitors potentially useful for the treatment of anxiety disorders, asthma, cardiomyopathy, diabetes, fibrosis, heart failure, hypertension and allergy, among others.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has discovered new GTPase KRAS inhibitors potentially useful for the treatment of cancer.

China Pharmaceutical University and the Chongqing Innovation Institute, China Pharmaceutical University have synthesized new asiaticoside saponin compounds reported to be useful for the treatment of inflammation, cancer and ulcerative colitis.

Blossomhill Therapeutics Inc. has patented new EGFR (HER1; erbB1) mutant inhibitors that are potentially useful for the treatment of cancer.

Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s disease.